About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
IP: M Mar Mañu Pereira Collaborators: Francisco González Romero, Francisco González Romero, Francisco González Romero, Ángela Menárguez López, Ángela Menárguez López Funding agency: EUROPEAN COMMISSION Funding: 267500 Reference: REALISED Duration: 01/01/2025 - 31/12/2029
IP: Miguel Segura Ginard Collaborators: Maria Jose Pérez García, Marta Miera Maluenda, Adria Molero Valenzuela, Lucas Moreno Martín-Retortillo Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 150000 Reference: 2024 PROD 00054 Duration: 02/12/2024 - 01/06/2026
IP: M Mar Mañu Pereira Collaborators: Sara Isabel Reidel , Núria Torquet i Luna, Esther García Pagès Funding agency: EUROPEAN COMMISSION Funding: 221875 Reference: HEMAFAIR/EC/WIDERA-2023-ACCESS-02-01/2023/MAÑU Duration: 01/06/2024 - 30/06/2027
IP: M Mar Mañu Pereira Collaborators: Sara Isabel Reidel , Sara Isabel Reidel , Miguel Chillon Rodriguez, Esther García Pagès, Raquel Mosull del Campo, Raquel Mosull del Campo, Simon Schwartz Navarro, Agustín Arasanz Duque, Sandra Mancilla Zamora, Anna Collado Gimbert, Marc Miquel Moltó Abad, Ángela Menárguez López, Ángela Menárguez López, Ángela Menárguez López, Claire Diot Funding agency: EUROPEAN COMMISSION Funding: 771525 Reference: ERDERA_MAÑU_EC_HLTH2023-DISEASE-07-01/2023 Duration: 01/09/2024 - 31/08/2031
The projects, selected under the 2026 Health Research and CaixaImpulse Health Innovation calls, address topics ranging from new therapies for childhood neurological disorders and Parkinson’s disease to the treatment of mitochondrial diseases and cancer.
A new publication describes the creation of this initiative, which has facilitated access to genomic studies for more than 900 pediatric patients with cancer from across Spain.
The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.
